Does Anthem (Elevance Health) Cover Liraglutide?

Anthem's Current Formulary Placement for Liraglutide

Anthem (Elevance Health) lists liraglutide on its commercial formulary for both chronic weight management and glycemic control in type 2 diabetes. The drug sits on a non-preferred specialty tier (Tier 4 or Tier 5 depending on the specific Anthem plan variant), which means higher cost-sharing compared to preferred generics or brand-name medications on lower tiers.

What the Tier Placement Means for Your Copay

On a Tier 4 or 5 placement, members typically face either a percentage-based coinsurance (often 25% to 40% of the drug's negotiated cost) or a flat specialty copay ranging from $150 to $300 per fill. For a drug with a manufacturer list price near $1,349 per month, out-of-pocket costs after insurance can still run $200 to $400 monthly before any deductible is met.

Formulary Variation Across Anthem Plans

Anthem operates under the Elevance Health umbrella across more than a dozen states, and formulary details differ by state, employer group, and plan metal level. An Anthem Blue Cross plan in California may classify liraglutide on a different tier than an Anthem Blue Cross Blue Shield plan in Virginia. Always verify your specific plan's formulary by logging into the Anthem member portal or calling the number on the back of your insurance card. The Summary of Benefits and Coverage (SBC) document your employer provides during open enrollment also lists tier structures.

Exchange Plans vs. Employer-Sponsored Plans

Anthem marketplace (ACA exchange) plans sometimes exclude GLP-1 receptor agonists for weight management entirely, covering them only for the type 2 diabetes indication. Employer-sponsored group plans are more likely to include the weight-management indication, though with the prior authorization and step therapy requirements described below.

Prior Authorization Requirements

Anthem requires prior authorization (PA) for liraglutide across nearly all plan types. The PA process serves as a utilization management check, confirming the drug is medically necessary for the specific member.

Clinical Criteria Anthem Typically Requires

To approve liraglutide for chronic weight management, Anthem's PA criteria generally require:

• A body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia.
• Documentation that the patient has attempted and failed a structured diet and exercise program for at least 6 months.
• Completion of step therapy (see next section).
• Prescriber attestation that the medication is being used alongside continued lifestyle modification.

For the type 2 diabetes indication, criteria focus on inadequate glycemic control (A1c above target) despite metformin or another first-line oral agent, consistent with the American Diabetes Association Standards of Care [1].

How to Submit PA and Expected Timelines

Your prescribing clinician submits the PA request, typically via Anthem's online provider portal (Availity) or by fax. Standard review takes 5 to 15 business days. Urgent or expedited requests (for example, if the patient's clinical condition warrants faster access) can be processed within 72 hours. A 2023 AMA survey found that physicians spend an average of 14 hours per week on prior authorization tasks across all drugs, illustrating the administrative burden this process creates [2].

Tips to Improve PA Approval Odds

Include thorough chart notes. Attach lab results (fasting glucose, A1c, lipid panel), document the patient's weight history, and list all prior medications tried with dates and reasons for discontinuation. Incomplete submissions are the most common reason for PA delays or denials.

Step Therapy Requirements

Anthem mandates step therapy for liraglutide on most plans. This means members must try and fail (or demonstrate intolerance to) one or more lower-cost medications before Anthem will authorize liraglutide.

What Counts as a "Step" Drug

For weight management, Anthem typically requires a trial of at least one of the following before approving liraglutide:

• Oral phentermine (or phentermine-topiramate combination)
• Orlistat
• Naltrexone-bupropion (Contrave)

For type 2 diabetes, the usual first step is metformin, followed by a sulfonylurea or an SGLT2 inhibitor such as empagliflozin or dapagliflozin.

Duration of Required Step Trials

Most Anthem plans require 60 to 90 days on a step drug before the member qualifies for an exception. Documentation must show the step drug was either clinically ineffective (insufficient weight loss or A1c reduction) or caused intolerable side effects. The Endocrine Society's 2015 clinical practice guidelines on pharmacologic management of obesity acknowledge that individual response to anti-obesity medications varies significantly, supporting the clinical rationale for moving to a GLP-1 receptor agonist after an inadequate first-line trial [3].

Step Therapy Exceptions

If your prescriber determines that the required step drugs are medically inappropriate (for example, a patient with a seizure disorder who cannot safely take phentermine-topiramate, or a patient with uncontrolled hypertension contraindicating phentermine), they can request a step therapy exception. This exception request is submitted alongside the PA and should include clinical justification with supporting medical literature.

What the Clinical Evidence Shows

Liraglutide 3.0 mg (the dose approved for chronic weight management) demonstrated strong efficacy in the SCALE Obesity and Prediabetes trial, a randomized, double-blind study of 3,731 adults. Participants receiving liraglutide 3.0 mg daily lost a mean of 8.0% of body weight at 56 weeks, compared to 2.6% in the placebo group. Over 63% of liraglutide-treated participants achieved at least 5% weight loss [4]. That trial also showed a 7.2 mmHg reduction in systolic blood pressure in the liraglutide group.

Glycemic Benefits in Type 2 Diabetes

For type 2 diabetes, liraglutide 1.8 mg (marketed as Victoza) reduced A1c by 1.1 to 1.5 percentage points in the LEAD trial program. The LEADER cardiovascular outcomes trial (N=9,340) demonstrated a 13% relative risk reduction in the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke over a median 3.8-year follow-up (HR 0.87, 95% CI 0.78 to 0.97) [5]. This cardiovascular benefit is a key clinical differentiator that prescribers can cite in PA requests for patients with established cardiovascular disease or high cardiovascular risk.

Why Clinical Evidence Matters for Your PA

Anthem's medical directors review PA requests against published evidence. Citing specific trial data (the SCALE results, the LEADER cardiovascular outcomes) in the PA submission strengthens the case. Generic "the patient needs this medication" language is far less effective than "this patient with a BMI of 34, type 2 diabetes, and established coronary artery disease meets criteria supported by the LEADER trial showing a 13% reduction in major cardiovascular events."

How to Appeal an Anthem Denial

If Anthem denies liraglutide coverage, you have the right to appeal. The process involves two stages.

Stage 1: Internal Appeal

File the internal appeal within 180 days of the denial letter. Your prescriber submits a letter of medical necessity, peer-reviewed references, and any additional clinical documentation not included in the original PA request. Anthem must complete its internal review within 30 calendar days for non-urgent cases. For urgent situations (active health deterioration), Anthem processes expedited appeals within 72 hours.

Dr. Caroline Apovian, a former professor of medicine at Harvard Medical School and co-author of the Endocrine Society obesity treatment guidelines, has stated: "Patients with obesity deserve access to FDA-approved pharmacotherapy when lifestyle intervention alone is insufficient. Insurance barriers should not override clinical judgment" [3].

Stage 2: External Review (State IRO)

If the internal appeal is denied, members can escalate to an Independent Review Organization (IRO). This external review is mandated by the Affordable Care Act and most state insurance regulations. The IRO assigns a physician reviewer who is board-certified in a relevant specialty. The IRO decision is binding on Anthem. External reviews typically take 45 days for standard cases and 72 hours for expedited requests.

Common Reasons for Denial and How to Counter Them

The three most frequent denial reasons for liraglutide on Anthem plans are:

1. Incomplete step therapy. Counter by documenting all prior medication trials with start dates, end dates, doses, and specific reasons for failure.
2. Insufficient clinical documentation. Counter by submitting BMI measurements (at least two time points), relevant labs, and comorbidity diagnosis codes.
3. Off-formulary indication. If Anthem's formulary covers liraglutide for diabetes but not weight management on your plan, the appeal must argue medical necessity for the specific indication using published evidence.

Using a Manufacturer Savings Card with Anthem

Novo Nordisk, the manufacturer of branded Saxenda (liraglutide 3.0 mg), offers a savings card program for eligible commercially insured patients. The card can reduce out-of-pocket costs to as low as $25 per month for qualifying fills.

Eligibility Rules

The savings card works alongside Anthem commercial insurance but has restrictions. Patients covered under government-funded programs (Medicare Part D, Medicaid, Tricare, VA benefits) are not eligible. The card typically has an annual maximum benefit (often $200 per fill, up to a yearly cap). Verify current terms directly on the manufacturer's savings program page, as benefit amounts change annually.

Compounded Liraglutide as an Alternative

Some patients explore compounded liraglutide from 503B outsourcing pharmacies as a lower-cost alternative. Compounded versions are not covered by Anthem (they are not FDA-approved finished products), so the entire cost is out-of-pocket. Prices from compounding pharmacies range from $200 to $500 per month. The FDA has issued guidance noting that compounded drugs do not undergo the same manufacturing quality checks as commercially manufactured products [6].

Cost-Reduction Strategies Beyond Insurance

Even with Anthem coverage, out-of-pocket costs for liraglutide can be significant. Several strategies may help reduce the financial burden.

Pharmacy Shopping

Pricing varies substantially between pharmacies. Cash-pay prices for liraglutide range from roughly $700 to $1,100 per month depending on the pharmacy. Using a pharmacy price comparison tool before filling can save several hundred dollars per fill cycle. Specialty pharmacies affiliated with Anthem's pharmacy benefit manager (often CVS Caremark or Express Scripts, depending on your employer's contract) may offer preferred pricing.

Patient Assistance Programs

Novo Nordisk's Patient Assistance Program (PAP) provides free medication to uninsured or underinsured patients who meet income thresholds (generally at or below 400% of the Federal Poverty Level). This program is separate from the savings card and requires a new application every 12 months.

Therapeutic Alternatives on a Lower Tier

If cost is the primary barrier, discuss with your prescriber whether a therapeutically similar GLP-1 receptor agonist on a lower Anthem formulary tier might be appropriate. Some Anthem plans place semaglutide (Wegovy or Ozempic) or dulaglutide (Trulicity) on preferred tiers, though coverage and tier placement vary. The American Association of Clinical Endocrinology 2023 obesity algorithm supports a shared decision-making approach when selecting among GLP-1 receptor agonists based on efficacy, tolerability, and cost [7].

Anthem Coverage for Liraglutide: State-by-State Nuances

Anthem operates as a Blue Cross, Blue Cross Blue Shield, or Anthem-branded plan across states including California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin. Coverage policies are set at the state plan level, not nationally.

States with Stronger Consumer Protections

Some states have enacted laws requiring commercial insurers to cover FDA-approved anti-obesity medications. For example, several states now prohibit blanket exclusions of obesity drugs on state-regulated fully insured plans. If your state has such a law and your Anthem plan is a fully insured product (not a self-funded employer plan governed by ERISA), you may have additional use in an appeal.

Self-Funded Employer Plans

Large employers that self-fund their health plans through Anthem as an administrator set their own formulary and coverage rules. Self-funded plans are governed by federal ERISA law rather than state insurance mandates. If your employer's self-funded Anthem plan excludes liraglutide, state anti-obesity-drug coverage laws will not apply. In that scenario, your recourse is to request that your employer's benefits department add the drug to the formulary during the next plan year.

The American Medical Association House of Delegates has formally recognized obesity as a disease since 2013 and has called for insurers to remove barriers to evidence-based obesity treatments, a position that supports advocacy efforts directed at self-funded plan sponsors [8].

Practical Checklist: Getting Liraglutide Approved on Anthem

Follow these steps in order to maximize your chances of coverage:

1. Confirm your specific Anthem plan covers liraglutide by checking the formulary online or calling member services.
2. Complete any required step therapy (document everything in the chart).
3. Have your prescriber submit a PA with full clinical documentation: BMI, lab results, comorbidities, prior medication trials, and cited evidence (SCALE, LEADER).
4. If denied, file an internal appeal within 180 days with a detailed letter of medical necessity.
5. If the internal appeal fails, request an external IRO review.
6. While waiting, apply for the manufacturer savings card and explore pharmacy pricing.

Adults with a BMI of 30 kg/m² or greater who have completed Anthem's step therapy requirements and whose prescribers submit complete documentation with trial-level citations have the highest PA approval rates on the first submission.